Ligne de temps
Isabelle Staropoli
Ingénieur(e) de Recherche
07 oct. 2024
publication
Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting.
Lire plus30 sept. 2024
publication
Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies
Lire plus19 juil. 2024
publication
Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2.
Lire plus13 mars 2024
publication
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Lire plus13 déc. 2023
28 févr. 2023
publication
Exposure to Secreted Bacterial Factors Promotes HIV-1 Replication in CD4+ T Cells.
Lire plus14 févr. 2023
publication
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Lire plus24 janv. 2023
01 janv. 2023
17 nov. 2022
publication
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
Lire plus05 oct. 2022
publication
Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection.
Lire plus01 sept. 2022
publication
Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.
Lire plus04 juil. 2022
publication
Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
Lire plus17 juin 2022
news
New publication – Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2
Lire plus01 juin 2022
publication
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
Lire plus12 mars 2022
publication
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2.
Lire plus01 févr. 2022
26 janv. 2022
publication
Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry.
Lire plus01 nov. 2021
publication
Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study.
Lire plus18 août 2021
01 août 2021
publication
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
Lire plus08 juil. 2021
18 mai 2021
publication
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
Lire plus01 avr. 2021
publication
SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020
Lire plus01 janv. 2021
02 sept. 2020
publication
A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations
Lire plus01 sept. 2020
publication
Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France.
Lire plus06 déc. 2018
22 nov. 2016
publication
Guidelines for cloning, expression, purification and functional characterization of primary HIV-1 envelope glycoproteins
Lire plus03 juil. 2015
18 juin 2015
publication
A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity
Lire plus11 mai 2015
22 mai 2014
publication
Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry
Lire plus21 mai 2013
publication
HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines
Lire plus26 janv. 2012
30 nov. 2010
publication
New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection
Lire plus02 juil. 2008
publication
The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins
Lire plus01 janv. 2007
01 mars 2006
publication
Infection of dendritic cells (DCs), not DC-SIGN-mediated internalization of human immunodeficiency virus, is required for long-term transfer of virus to T cells
Lire plus01 mai 2005
publication
Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E
Lire plus26 avr. 2005
publication
Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals
Lire plus10 mars 2005
publication
Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis
Lire plus27 févr. 2003
publication
DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2
Lire plus22 nov. 2002
publication
Low levels of co-receptor CCR5 are sufficient to permit HIV envelope-mediated fusion with resting CD4 T cells
Lire plus12 nov. 2002
publication
HIV-1 entry into T-cells is not dependent on CD4 and CCR5 localization to sphingolipid-enriched, detergent-resistant, raft membrane domains
Lire plus26 févr. 2002
publication
Leukocyte elastase negatively regulates Stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4
Lire plus10 nov. 2000
publication
Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate
Lire plus01 déc. 1997
publication
Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice
Lire plus01 févr. 1996
publication
Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein
Lire plus01 juil. 1994
publication